Efficacy  ||| S:0 E:9 ||| NNP
of  ||| S:9 E:12 ||| IN
single-dose  ||| S:12 E:24 ||| JJ
intravenous  ||| S:24 E:36 ||| JJ
phenylbutazone  ||| S:36 E:51 ||| NN
and  ||| S:51 E:55 ||| CC
flunixin  ||| S:55 E:64 ||| JJ
meglumine  ||| S:64 E:74 ||| NNS
before ||| S:74 E:80 ||| RB
,  ||| S:80 E:82 ||| ,
during  ||| S:82 E:89 ||| IN
and  ||| S:89 E:93 ||| CC
after  ||| S:93 E:99 ||| IN
exercise  ||| S:99 E:108 ||| NN
in  ||| S:108 E:111 ||| IN
an  ||| S:111 E:114 ||| DT
experimental  ||| S:114 E:127 ||| JJ
reversible  ||| S:127 E:138 ||| JJ
model  ||| S:138 E:144 ||| NN
of  ||| S:144 E:147 ||| IN
foot  ||| S:147 E:152 ||| NN
lameness  ||| S:152 E:161 ||| NN
in  ||| S:161 E:164 ||| IN
horses  ||| S:164 E:171 ||| FW
Objective  ||| S:171 E:181 ||| FW
blinded  ||| S:181 E:189 ||| FW
efficacy  ||| S:189 E:198 ||| FW
data  ||| S:198 E:203 ||| NNS
during  ||| S:203 E:210 ||| IN
exercise  ||| S:210 E:219 ||| NN
are  ||| S:219 E:223 ||| VBP
lacking  ||| S:223 E:231 ||| VBG
on  ||| S:231 E:234 ||| IN
the  ||| S:234 E:238 ||| DT
use  ||| S:238 E:242 ||| NN
of  ||| S:242 E:245 ||| IN
single-dose  ||| S:245 E:257 ||| JJ
i.v.  ||| S:257 E:262 ||| CD
nonsteroidal  ||| S:262 E:275 ||| CD
anti-inflammatory  ||| S:275 E:293 ||| JJ
drugs  ||| S:293 E:299 ||| NNS
( ||| S:299 E:300 ||| -LRB-
NSAIDs ||| S:300 E:306 ||| NNP
)  ||| S:306 E:308 ||| -RRB-
before ||| S:308 E:314 ||| RB
,  ||| S:314 E:316 ||| ,
during  ||| S:316 E:323 ||| IN
and  ||| S:323 E:327 ||| CC
after  ||| S:327 E:333 ||| IN
exercise ||| S:333 E:341 ||| NN
.  ||| S:341 E:343 ||| .
Single  ||| S:343 E:350 ||| JJ
i.v.  ||| S:350 E:355 ||| CD
doses  ||| S:355 E:361 ||| NNS
of  ||| S:361 E:364 ||| IN
either  ||| S:364 E:371 ||| DT
phenylbutazone  ||| S:371 E:386 ||| NN
( ||| S:386 E:387 ||| -LRB-
PBZ ||| S:387 E:390 ||| NNP
)  ||| S:390 E:392 ||| -RRB-
or  ||| S:392 E:395 ||| CC
flunixin  ||| S:395 E:404 ||| JJ
meglumine  ||| S:404 E:414 ||| NNS
( ||| S:414 E:415 ||| -LRB-
FM ||| S:415 E:417 ||| NNP
)  ||| S:417 E:419 ||| -RRB-
would  ||| S:419 E:425 ||| MD
prove  ||| S:425 E:431 ||| VB
more  ||| S:431 E:436 ||| JJR
efficacious  ||| S:436 E:448 ||| NN
than  ||| S:448 E:453 ||| IN
negative  ||| S:453 E:462 ||| JJ
saline  ||| S:462 E:469 ||| JJ
control  ||| S:469 E:477 ||| NN
( ||| S:477 E:478 ||| -LRB-
SAL ||| S:478 E:481 ||| NNP
)  ||| S:481 E:483 ||| -RRB-
before ||| S:483 E:489 ||| RB
,  ||| S:489 E:491 ||| ,
during  ||| S:491 E:498 ||| IN
and  ||| S:498 E:502 ||| CC
after  ||| S:502 E:508 ||| IN
exercise  ||| S:508 E:517 ||| NN
in  ||| S:517 E:520 ||| IN
a  ||| S:520 E:522 ||| DT
reversible  ||| S:522 E:533 ||| JJ
model  ||| S:533 E:539 ||| NN
of  ||| S:539 E:542 ||| IN
foot  ||| S:542 E:547 ||| NN
lameness ||| S:547 E:555 ||| NN
.  ||| S:555 E:557 ||| .
Six  ||| S:557 E:561 ||| CD
Quarter  ||| S:561 E:569 ||| NNP
Horse  ||| S:569 E:575 ||| NNP
mares  ||| S:575 E:581 ||| NN
had  ||| S:581 E:585 ||| VBD
lameness  ||| S:585 E:594 ||| JJ
induced  ||| S:594 E:602 ||| NN
by  ||| S:602 E:605 ||| IN
tightening  ||| S:605 E:616 ||| VBG
a  ||| S:616 E:618 ||| DT
set  ||| S:618 E:622 ||| NN
screw  ||| S:622 E:628 ||| NN
against  ||| S:628 E:636 ||| IN
a  ||| S:636 E:638 ||| DT
heart  ||| S:638 E:644 ||| NN
bar  ||| S:644 E:648 ||| NN
shoe  ||| S:648 E:653 ||| NN
1  ||| S:653 E:655 ||| CD
h  ||| S:655 E:657 ||| NNS
prior  ||| S:657 E:663 ||| RB
to  ||| S:663 E:666 ||| TO
treatment ||| S:666 E:675 ||| NN
.  ||| S:675 E:677 ||| .
Randomised  ||| S:677 E:688 ||| JJ
blinded  ||| S:688 E:696 ||| JJ
treatments  ||| S:696 E:707 ||| NNS
included  ||| S:707 E:716 ||| VBD
PBZ  ||| S:716 E:720 ||| NNP
( ||| S:720 E:721 ||| -LRB-
4.4  ||| S:721 E:725 ||| FW
mg ||| S:725 E:727 ||| FW
/ ||| S:727 E:728 ||| FW
kg  ||| S:728 E:731 ||| FW
bwt  ||| S:731 E:735 ||| FW
i.v. ||| S:735 E:739 ||| FW
) ||| S:739 E:740 ||| -RRB-
,  ||| S:740 E:742 ||| ,
FM  ||| S:742 E:745 ||| NNP
( ||| S:745 E:746 ||| -LRB-
1.1  ||| S:746 E:750 ||| FW
mg ||| S:750 E:752 ||| FW
/ ||| S:752 E:753 ||| FW
kg  ||| S:753 E:756 ||| FW
bwt  ||| S:756 E:760 ||| FW
i.v. ||| S:760 E:764 ||| FW
) ||| S:764 E:765 ||| -RRB-
,  ||| S:765 E:767 ||| ,
and  ||| S:767 E:771 ||| CC
SAL  ||| S:771 E:775 ||| NNP
( ||| S:775 E:776 ||| -LRB-
1  ||| S:776 E:778 ||| CD
ml ||| S:778 E:780 ||| CD
/ ||| S:780 E:781 ||| CD
45  ||| S:781 E:784 ||| CD
kg  ||| S:784 E:787 ||| CD
i.v. ||| S:787 E:791 ||| CD
) ||| S:791 E:792 ||| -RRB-
.  ||| S:792 E:794 ||| .
Heart  ||| S:794 E:800 ||| NN
rate  ||| S:800 E:805 ||| NN
and  ||| S:805 E:809 ||| CC
lameness  ||| S:809 E:818 ||| JJ
score  ||| S:818 E:824 ||| NN
( ||| S:824 E:825 ||| -LRB-
LS ||| S:825 E:827 ||| NNP
)  ||| S:827 E:829 ||| -RRB-
were  ||| S:829 E:834 ||| VBD
recorded  ||| S:834 E:843 ||| VBN
at  ||| S:843 E:846 ||| IN
rest ||| S:846 E:850 ||| NN
;  ||| S:850 E:852 ||| :
every  ||| S:852 E:858 ||| DT
20  ||| S:858 E:861 ||| CD
min  ||| S:861 E:865 ||| NN
after  ||| S:865 E:871 ||| IN
lameness  ||| S:871 E:880 ||| JJ
induction  ||| S:880 E:890 ||| NN
for  ||| S:890 E:894 ||| IN
5  ||| S:894 E:896 ||| CD
h  ||| S:896 E:898 ||| NNS
and  ||| S:898 E:902 ||| CC
at  ||| S:902 E:905 ||| IN
the  ||| S:905 E:909 ||| DT
end  ||| S:909 E:913 ||| NN
of  ||| S:913 E:916 ||| IN
2  ||| S:916 E:918 ||| CD
min  ||| S:918 E:922 ||| NNS
treadmill  ||| S:922 E:932 ||| VBP
workloads  ||| S:932 E:942 ||| VBN
of  ||| S:942 E:945 ||| IN
2  ||| S:945 E:947 ||| CD
and  ||| S:947 E:951 ||| CC
4  ||| S:951 E:953 ||| CD
m ||| S:953 E:954 ||| CD
/ ||| S:954 E:955 ||| CD
s ||| S:955 E:956 ||| NNS
.  ||| S:956 E:958 ||| .
Heart  ||| S:958 E:964 ||| NN
rate  ||| S:964 E:969 ||| NN
was  ||| S:969 E:973 ||| VBD
also  ||| S:973 E:978 ||| RB
recorded  ||| S:978 E:987 ||| VBN
from  ||| S:987 E:992 ||| IN
0.5-60  ||| S:992 E:999 ||| CD
min  ||| S:999 E:1003 ||| JJ
post  ||| S:1003 E:1008 ||| NN
exercise ||| S:1008 E:1016 ||| NN
.  ||| S:1016 E:1018 ||| .
Results  ||| S:1018 E:1026 ||| NNS
were  ||| S:1026 E:1031 ||| VBD
compared  ||| S:1031 E:1040 ||| VBN
using  ||| S:1040 E:1046 ||| VBG
RM  ||| S:1046 E:1049 ||| NNP
ANOVA  ||| S:1049 E:1055 ||| NNP
and  ||| S:1055 E:1059 ||| CC
Student-Newman-Keul ||| S:1059 E:1078 ||| NNP
's  ||| S:1078 E:1081 ||| POS
test  ||| S:1081 E:1086 ||| NN
( ||| S:1086 E:1087 ||| -LRB-
HR ||| S:1087 E:1089 ||| NNP
)  ||| S:1089 E:1091 ||| -RRB-
and  ||| S:1091 E:1095 ||| CC
Wilcoxon  ||| S:1095 E:1104 ||| NNP
signed  ||| S:1104 E:1111 ||| VBD
rank  ||| S:1111 E:1116 ||| JJ
test  ||| S:1116 E:1121 ||| NN
( ||| S:1121 E:1122 ||| -LRB-
% ||| S:1122 E:1123 ||| NN
ΔLS ||| S:1123 E:1126 ||| NNP
)  ||| S:1126 E:1128 ||| -RRB-
with  ||| S:1128 E:1133 ||| IN
significance  ||| S:1133 E:1146 ||| NN
set  ||| S:1146 E:1150 ||| VBN
at  ||| S:1150 E:1153 ||| IN
P  ||| S:1153 E:1155 ||| NN
< ||| S:1155 E:1157 ||| SYM
0.05 ||| S:1157 E:1161 ||| CD
.  ||| S:1161 E:1163 ||| .
Pre-exercise  ||| S:1163 E:1176 ||| JJ
mean  ||| S:1176 E:1181 ||| JJ
HR  ||| S:1181 E:1184 ||| NNP
was  ||| S:1184 E:1188 ||| VBD
decreased  ||| S:1188 E:1198 ||| VBN
for  ||| S:1198 E:1202 ||| IN
both  ||| S:1202 E:1207 ||| DT
NSAIDs  ||| S:1207 E:1214 ||| JJ
compared  ||| S:1214 E:1223 ||| VBN
to  ||| S:1223 E:1226 ||| TO
SAL  ||| S:1226 E:1230 ||| NNP
from  ||| S:1230 E:1235 ||| IN
1 ||| S:1235 E:1236 ||| CD
: ||| S:1236 E:1237 ||| :
20-4  ||| S:1237 E:1242 ||| CD
h  ||| S:1242 E:1244 ||| JJ
post  ||| S:1244 E:1249 ||| NN
treatment  ||| S:1249 E:1259 ||| NN
( ||| S:1259 E:1260 ||| -LRB-
P  ||| S:1260 E:1262 ||| NNP
< ||| S:1262 E:1264 ||| SYM
0.05 ||| S:1264 E:1268 ||| CD
) ||| S:1268 E:1269 ||| -RRB-
.  ||| S:1269 E:1271 ||| .
Pre-exercise  ||| S:1271 E:1284 ||| JJ
mean  ||| S:1284 E:1289 ||| JJ
% ||| S:1289 E:1290 ||| NN
ΔLS  ||| S:1290 E:1294 ||| NNP
was  ||| S:1294 E:1298 ||| VBD
decreased  ||| S:1298 E:1308 ||| VBN
for  ||| S:1308 E:1312 ||| IN
PBZ  ||| S:1312 E:1316 ||| NNP
( ||| S:1316 E:1317 ||| -LRB-
1 ||| S:1317 E:1318 ||| LS
: ||| S:1318 E:1319 ||| :
20-4  ||| S:1319 E:1324 ||| CD
h ||| S:1324 E:1325 ||| CD
)  ||| S:1325 E:1327 ||| -RRB-
and  ||| S:1327 E:1331 ||| CC
FM  ||| S:1331 E:1334 ||| NNP
( ||| S:1334 E:1335 ||| -LRB-
1-4  ||| S:1335 E:1339 ||| FW
h ||| S:1339 E:1340 ||| FW
)  ||| S:1340 E:1342 ||| -RRB-
compared  ||| S:1342 E:1351 ||| VBN
to  ||| S:1351 E:1354 ||| TO
SAL  ||| S:1354 E:1358 ||| NNP
( ||| S:1358 E:1359 ||| -LRB-
P  ||| S:1359 E:1361 ||| NNP
< ||| S:1361 E:1363 ||| SYM
0.01 ||| S:1363 E:1367 ||| CD
) ||| S:1367 E:1368 ||| -RRB-
.  ||| S:1368 E:1370 ||| .
With  ||| S:1370 E:1375 ||| IN
exercise ||| S:1375 E:1383 ||| NN
,  ||| S:1383 E:1385 ||| ,
there  ||| S:1385 E:1391 ||| EX
were  ||| S:1391 E:1396 ||| VBD
no  ||| S:1396 E:1399 ||| DT
HR  ||| S:1399 E:1402 ||| NNP
differences  ||| S:1402 E:1414 ||| NNS
between  ||| S:1414 E:1422 ||| IN
treatments  ||| S:1422 E:1433 ||| NNS
( ||| S:1433 E:1434 ||| -LRB-
P  ||| S:1434 E:1436 ||| NNP
>  ||| S:1436 E:1438 ||| CD
0.05 ||| S:1438 E:1442 ||| CD
) ||| S:1442 E:1443 ||| -RRB-
,  ||| S:1443 E:1445 ||| ,
but  ||| S:1445 E:1449 ||| CC
mean  ||| S:1449 E:1454 ||| JJ
% ||| S:1454 E:1455 ||| NN
ΔLS  ||| S:1455 E:1459 ||| NNP
was  ||| S:1459 E:1463 ||| VBD
decreased  ||| S:1463 E:1473 ||| VBN
for  ||| S:1473 E:1477 ||| IN
both  ||| S:1477 E:1482 ||| DT
NSAIDs  ||| S:1482 E:1489 ||| JJ
compared  ||| S:1489 E:1498 ||| VBN
to  ||| S:1498 E:1501 ||| TO
SAL  ||| S:1501 E:1505 ||| NNP
( ||| S:1505 E:1506 ||| -LRB-
P  ||| S:1506 E:1508 ||| NNP
< ||| S:1508 E:1510 ||| SYM
0.01 ||| S:1510 E:1514 ||| CD
) ||| S:1514 E:1515 ||| -RRB-
.  ||| S:1515 E:1517 ||| .
Mean  ||| S:1517 E:1522 ||| JJ
recovery  ||| S:1522 E:1531 ||| NN
HR  ||| S:1531 E:1534 ||| NNP
was  ||| S:1534 E:1538 ||| VBD
decreased  ||| S:1538 E:1548 ||| VBN
for  ||| S:1548 E:1552 ||| IN
PBZ  ||| S:1552 E:1556 ||| NNP
and  ||| S:1556 E:1560 ||| CC
FM  ||| S:1560 E:1563 ||| NNP
from  ||| S:1563 E:1568 ||| IN
1-60  ||| S:1568 E:1573 ||| NNP
min  ||| S:1573 E:1577 ||| VBD
compared  ||| S:1577 E:1586 ||| VBN
to  ||| S:1586 E:1589 ||| TO
SAL  ||| S:1589 E:1593 ||| NNP
( ||| S:1593 E:1594 ||| -LRB-
P  ||| S:1594 E:1596 ||| NNP
< ||| S:1596 E:1598 ||| SYM
0.05 ||| S:1598 E:1602 ||| CD
) ||| S:1602 E:1603 ||| -RRB-
.  ||| S:1603 E:1605 ||| .
PBZ  ||| S:1605 E:1609 ||| NNP
and  ||| S:1609 E:1613 ||| CC
FM  ||| S:1613 E:1616 ||| NNP
demonstrated  ||| S:1616 E:1629 ||| VBD
definitive  ||| S:1629 E:1640 ||| JJ
clinical  ||| S:1640 E:1649 ||| JJ
efficacy  ||| S:1649 E:1658 ||| NN
after  ||| S:1658 E:1664 ||| IN
single  ||| S:1664 E:1671 ||| JJ
i.v.  ||| S:1671 E:1676 ||| CD
doses  ||| S:1676 E:1682 ||| NNS
before ||| S:1682 E:1688 ||| RB
,  ||| S:1688 E:1690 ||| ,
during  ||| S:1690 E:1697 ||| IN
and  ||| S:1697 E:1701 ||| CC
after  ||| S:1701 E:1707 ||| IN
exercise ||| S:1707 E:1715 ||| NN
.  ||| S:1715 E:1717 ||| .
Use  ||| S:1717 E:1721 ||| NN
of  ||| S:1721 E:1724 ||| IN
single  ||| S:1724 E:1731 ||| JJ
i.v.  ||| S:1731 E:1736 ||| CD
doses  ||| S:1736 E:1742 ||| NNS
during  ||| S:1742 E:1749 ||| IN
competition  ||| S:1749 E:1761 ||| NN
may  ||| S:1761 E:1765 ||| MD
mask  ||| S:1765 E:1770 ||| VB
lameness  ||| S:1770 E:1779 ||| NNS
and  ||| S:1779 E:1783 ||| CC
may  ||| S:1783 E:1787 ||| MD
affect  ||| S:1787 E:1794 ||| VB
the  ||| S:1794 E:1798 ||| DT
ability  ||| S:1798 E:1806 ||| NN
of  ||| S:1806 E:1809 ||| IN
judges  ||| S:1809 E:1816 ||| NNS
in  ||| S:1816 E:1819 ||| IN
determining  ||| S:1819 E:1831 ||| VBG
the  ||| S:1831 E:1835 ||| DT
soundness  ||| S:1835 E:1845 ||| NN
of  ||| S:1845 E:1848 ||| IN
horses  ||| S:1848 E:1855 ||| NNS
in  ||| S:1855 E:1858 ||| IN
competition ||| S:1858 E:1869 ||| NN
.  ||| S:1869 E:1871 ||| .
